ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update

06 Feb 2025 16:30:00 By Nasdaq GlobeNewswire

Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS

05 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

17 Jan 2025 16:30:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

12 Jan 2025 11:00:00 By Nasdaq GlobeNewswire

Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

06 Jan 2025 16:30:00 By Nasdaq GlobeNewswire

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

06 Jan 2025 02:00:43 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20 Dec 2024 16:30:00 By Nasdaq GlobeNewswire

Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome

19 Dec 2024 16:05:00 By Nasdaq GlobeNewswire

Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

19 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

Ultragenyx to Participate in Investor Conferences in December

26 Nov 2024 16:30:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20 Nov 2024 16:30:00 By Nasdaq GlobeNewswire

Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit

09 Nov 2024 10:30:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update

05 Nov 2024 16:01:00 By Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update

29 Oct 2024 16:05:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

18 Oct 2024 16:30:00 By Nasdaq GlobeNewswire

Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta

07 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

03 Oct 2024 16:30:00 By Nasdaq GlobeNewswire

Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting

26 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

18 Sep 2024 17:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

16 Sep 2024 12:51:10 By NetDania Notify